CN112545978A - 具有持效抗幽门螺杆菌作用的口腔护理凝胶及其制备方法 - Google Patents
具有持效抗幽门螺杆菌作用的口腔护理凝胶及其制备方法 Download PDFInfo
- Publication number
- CN112545978A CN112545978A CN202011480380.5A CN202011480380A CN112545978A CN 112545978 A CN112545978 A CN 112545978A CN 202011480380 A CN202011480380 A CN 202011480380A CN 112545978 A CN112545978 A CN 112545978A
- Authority
- CN
- China
- Prior art keywords
- helicobacter pylori
- oral care
- care gel
- stirring
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 51
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 47
- 230000000694 effects Effects 0.000 title claims abstract description 30
- 230000002459 sustained effect Effects 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 38
- 238000003756 stirring Methods 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 22
- 239000008213 purified water Substances 0.000 claims abstract description 22
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 19
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940104261 taurate Drugs 0.000 claims abstract description 12
- 239000003899 bactericide agent Substances 0.000 claims abstract description 11
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 11
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 10
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 10
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 10
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 10
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 10
- 229940041616 menthol Drugs 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000811 xylitol Substances 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 10
- 229960002675 xylitol Drugs 0.000 claims abstract description 10
- 235000010447 xylitol Nutrition 0.000 claims abstract description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 9
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 9
- 229920002401 polyacrylamide Polymers 0.000 claims abstract description 9
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000004094 surface-active agent Substances 0.000 claims abstract description 8
- 238000004090 dissolution Methods 0.000 claims abstract description 6
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 6
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 5
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 5
- 229920001992 poloxamer 407 Polymers 0.000 claims description 5
- 229940044476 poloxamer 407 Drugs 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 229940083575 sodium dodecyl sulfate Drugs 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 2
- 239000000499 gel Substances 0.000 abstract description 40
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
- 210000000214 mouth Anatomy 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 208000007107 Stomach Ulcer Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 201000005917 gastric ulcer Diseases 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 208000007117 Oral Ulcer Diseases 0.000 description 3
- 208000025157 Oral disease Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 208000030194 mouth disease Diseases 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 229940034610 toothpaste Drugs 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000032139 Halitosis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 206010044029 Tooth deposit Diseases 0.000 description 2
- 241001148470 aerobic bacillus Species 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- 208000001277 chronic periodontitis Diseases 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- -1 dimethyl taurate Chemical compound 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及口腔凝胶。具有持效抗幽门螺杆菌作用的口腔护理凝胶，它包括如下质量百分比的：杀菌剂0.05％‑0.2％，表面活性剂1％‑5％，羧甲基纤维素5％‑1.5％，聚丙烯酰基二甲基牛磺酸铵0.1％‑0.3％，肉豆蔻酸异丙酯0.1％‑0.5％，甘草酸0.05％‑0.5％，薄荷醇0.05％‑0.3％，木糖醇0.5％‑5％，纳米铂金微量，纯化水，余量。按照配方，将纯化水分成两份，一份加入按羧甲基纤维素、聚丙烯酰基二甲基牛磺酸铵中搅拌溶解30—40min，直至变成透明凝胶状，得体系A；表面活性剂、甘草酸、木糖醇、薄荷醇加入另一份纯化水中，在40—50℃温度下搅拌至完成溶解，得体系B；将杀菌剂、纳米铂金、肉豆蔻酸异丙酯加入到体系B中，搅拌均匀，得体系C；在搅拌的条件下，将体系C加入体系A中，混合均匀，即得的口腔护理凝胶能持续发生作用。
Description
技术领域
本发明涉及口腔护理，尤其涉及一种抗幽门螺杆菌的口腔护理凝胶。
背景技术
幽门螺旋杆菌是一种革兰氏阴性菌，螺旋形、微需氧、对生长条件十分苛刻，是所知的能够在胃、口生存的微生物种类。自上世纪80年代起，国内外学者不断在胃炎、胃溃疡等临床患者胃中分离培养出幽门螺杆菌，并确认其为多种消化系统疾病的主要致病因素后，已引起广泛关注，人们对慢性胃炎、消化性溃疡及胃癌等疾病的发生和发展的概念上产生了彻底的变革。2017年幽门螺杆菌已被世界卫生组织列为Ⅰ类致癌因子，被国际公认的胃溃疡、十二指肠溃疡、更是胃癌致病菌，也是口臭、口腔溃疡、慢性咽炎、牙周炎的元凶之一。
国内外众多研究中显示，胃中的幽门螺杆菌与口腔中幽门螺杆具有密切关系，因此在临床中治疗消化系统疾病时不仅要清除胃内幽门螺杆菌,同时还需要考虑口腔内幽门螺杆菌的感染和传播，即口腔幽门螺杆菌的清除可以通过避免交叉感染从而降低胃幽门螺杆菌复发率，也可避免口臭、腔溃疡、慢性咽炎、牙周炎的发生。
口腔幽门螺杆菌主要分布在唾液、牙菌斑、龈沟液中，目前抗生素可以清除幽门螺旋杆菌，但仅限于胃部，对于口腔里的幽门螺旋杆菌则不易清除，且随着抗生素的使用频率越高，幽门螺杆菌的耐药性越强，导致疾病根除效果降低，反复发作。因此清除口腔幽门螺旋杆菌，应该定期清理牙结石、牙垢、牙渍。但目前市面上功效抗幽门螺杆菌牙膏、漱口液产品，杀菌能力弱，且其杀菌作用时间短，只能在刷牙和漱口期间起作用，在清洁口腔后，口腔内细菌又快速滋生，不能发挥持久抗菌作用。
发明内容
本发明旨在克服现有技术的缺陷，提供一种具有持效抗幽门螺杆菌作用的口腔护理凝胶及其制备方法。本发明能持续作用，长久保障人体口腔的卫生。
本发明是这样实现的：
具有持效抗幽门螺杆菌作用的口腔护理凝胶，它包括如下质量百分比的：
所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，所述的杀菌剂为O-伞花烃-5-醇、西吡氯铵或葡萄糖酸氯己定中的一种。
所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，所述的表面活性剂为十二烷基硫酸钠、椰油酰胺丙基甜菜碱或泊洛沙姆407中的一种。
所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，所述的纳米铂金微量浓度为0.5ppm-5ppm。
所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，所述的纳米铂金的粒径范围在0.5nm-5.0nm。
一种如所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶的制备方法，包括以下步骤：
(1)将配方中的纯化水分成两份，一份纯化水加入按配比量称取的羧甲基纤维素、聚丙烯酰基二甲基牛磺酸铵中搅拌溶解30—40min，直至变成透明凝胶状，得体系A；
(2)按配比量称量表面活性剂、甘草酸、木糖醇、薄荷醇加入另一份纯化水中，在40—50℃温度下搅拌至完成溶解，得体系B；
(3)将配比量的杀菌剂、纳米铂金、肉豆蔻酸异丙酯加入到体系B中，搅拌均匀，得体系C。
(4)在搅拌的条件下，将体系C加入体系A中，混合均匀，即得所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶。
本发明以O-伞花烃-5-醇、西吡氯铵或葡萄糖酸氯己定为杀菌剂，复配聚丙烯酰基二甲基牛磺酸铵、肉豆蔻酸异丙酯、纳米铂金等成分。聚丙烯酰基二甲基牛磺酸铵是一种高分子化合物，分子结构中不含E0基团，生物降解性好，安全性高，能与皮肤黏膜有良好的亲和力，吸附于口腔黏膜，维持长效作用。肉豆蔻酸异丙酯与皮肤黏膜有良好的亲和力，与聚丙烯酰基二甲基牛磺酸铵合用，发挥协同亲和皮肤黏膜作用。铂金作为稀有贵金属，加工成纳米级别颗粒后再分散成胶体溶液，具有独特的生物催化功能和促渗透作用，与抗菌剂合用，显著增强杀菌力。和现有技术相比，本发明以聚丙烯酰基二甲基牛磺酸铵、肉豆蔻酸异丙酯、纳米铂金与杀菌剂合用，聚丙烯酰基二甲基牛磺酸铵在口腔黏膜形成持久吸附层，同时聚丙烯酰基二甲基牛磺酸铵作为载体负载着肉豆蔻酸异丙酯、纳米铂金与杀菌剂，在口腔中发挥持效抗幽门螺杆菌作用，抑制口腔细菌滋生。
本发明中，甘草酸来源于豆科植物甘草的干燥根，具有特殊的甜味和淡淡的中草药气味，具有止咳祉疾，缓急止痛，抑菌、消炎、除臭效果。复配木糖醇、薄荷醇获得舒适的口感，能提神醒脑、清新口气、清凉止疼。
本发明所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶，能快速、持久抑杀幽门螺杆菌，同时对口腔中其他厌氧菌和好氧菌具有持久抗抑菌效果，有效辅助防治龋病、牙周病、口腔溃疡病等口腔病和预防胃溃疡、十二指肠溃疡、胃癌等胃病的，且用途广，可用作牙膏刷牙、口腔含漱以及口腔溃疡等口腔黏膜涂敷，多用途合一。
具体实施方式
本发明具有持效抗幽门螺杆菌作用的口腔护理凝胶，它包括如下质量百分比的：
所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，所述的杀菌剂为O-伞花烃-5-醇、西吡氯铵或葡萄糖酸氯己定中的一种。
所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，所述的表面活性剂为十二烷基硫酸钠、椰油酰胺丙基甜菜碱或泊洛沙姆407中的一种。
所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，所述的纳米铂金微量浓度为0.5ppm-5ppm。
所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，所述的纳米铂金的粒径范围在0.5nm-5.0nm。
所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶的制备方法，包括以下步骤：
(1)将配方中的纯化水分成两份，一份纯化水加入按配比量称取的羧甲基纤维素、聚丙烯酰基二甲基牛磺酸铵中搅拌溶解30—40min，直至变成透明凝胶状，得体系A；
(2)按配比量称量表面活性剂、甘草酸、木糖醇、薄荷醇加入另一份纯化水中，在40—50℃温度下搅拌至完成溶解，得体系B；
(3)将配比量的杀菌剂、纳米铂金、肉豆蔻酸异丙酯加入到体系B中，搅拌均匀，得体系C。
(4)在搅拌的条件下，将体系C加入体系A中，混合均匀，即得所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶。
实施例1
(1)将1.2g羧甲基纤维素、0.18g聚丙烯酰基二甲基牛磺酸铵加入46.61g纯化水中搅拌溶解35min，变成透明凝胶状，得体系A。
(2)将3g泊洛沙姆407、0.08g甘草酸、2g木糖醇、0.1g薄荷醇加入另46.61g纯化水中，在45℃温度下搅拌至完成溶解，得B体系。
(3)将0.1g O-伞花烃-5-醇、0.06mg纳米铂金、0.12g肉豆蔻酸异丙酯加入到体系B中，搅拌均匀，得C体系。
(4)在搅拌的条件下，将C体系加入A体系中，混合均匀，即得所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶。
实施例2
(1)将0.8g羧甲基纤维素、0.25g酰基二甲基牛磺酸铵加入47.35g纯化水中搅拌溶解35min，变成透明凝胶状，得体系A。
(2)将1.5g十二烷基硫酸钠、0.3g甘草酸、1.8g木糖醇、0.08g薄荷醇加入47.35g纯化水中，在45℃温度下搅拌至完成溶解，得B体系。
(3)将0.17g葡萄糖酸氯己定、0.2mg纳米铂金、0.4g肉豆蔻酸异丙酯加入到体系B中，搅拌均匀，得C体系。
(4)在搅拌的条件下，将C体系加入A体系中，混合均匀，即得所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶。
实施例3
(1)将1.4g羧甲基纤维素、0.12g聚丙烯酰基二甲基牛磺酸铵加入46.14g纯化水中搅拌溶解35min，变成透明凝胶状，得体系A。
(2)将2.5g椰油酰胺丙基甜菜碱、0.2g甘草酸、3g木糖醇、0.22g薄荷醇加入46.14g纯化水中，在45℃温度下搅拌至完成溶解，得B体系。
(3)将0.08g西吡氯铵、0.12mg纳米铂金、0.2g肉豆蔻酸异丙酯加入到体系B中，搅拌均匀，得C体系。
(4)在搅拌的条件下，将C体系加入A体系中，混合均匀，即得所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶。
实施例4
(1)将0.6g羧甲基纤维素、0.28g聚丙烯酰基二甲基牛磺酸铵加入44.57g纯化水中搅拌溶解35min，变成透明凝胶状，得体系A。
(2)将4g泊洛沙姆407、0.4g甘草酸、5g木糖醇、0.16g薄荷醇加入44.57g纯化水中，在45℃温度下搅拌至完成溶解，得B体系。
(3)将0.12g西吡氯铵、0.4mg纳米铂金、0.3g肉豆蔻酸异丙酯加入到体系B中，搅拌均匀，得C体系。
(4)在搅拌的条件下，将C体系加入A体系中，混合均匀，即得所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶。
实施例实验数据
根据GB 15979-2002《一次性使用卫生用品卫生标准》附录C进行抑菌实验,取上述各实施例1-4口腔护理凝胶，以凝胶:水为1:4的稀释液作用2min，对幽门螺杆菌、金黄色葡萄球菌、白色念珠菌、大肠杆菌及变性链球菌平均抑菌率达到100％。
参照2002年版《消毒技术规范》第二部分2.1.8.5的滞留抑菌效果试验方法，以安全性的金黄色葡萄球菌ATCC27217(此株金黄色葡萄球菌是一种低毒性、对青霉素敏感、对四环素有抗药性的色素株，曾用于许多试验研究，没有任何严重副作用)作为试验菌，以上述各实施例1-4口腔护理凝胶为试验产品，进行滞留抑菌效果试验，2小时后的滞留抑菌率大于90％，6小时后的滞留抑菌率大于80％，12小时后的滞留抑菌率大于60％。
根据2002年版《消毒技术规范》第二部分2.3.1进行急性经口毒性试验，取上述各实施例1-4口腔护理凝胶给小鼠灌胃，每20g体重小鼠灌胃100mg，连续观察14天。结果在14天内小鼠未表现异常现象，无死亡例数，解剖观察小鼠的脏器，未发现异常，即表明该口腔护理凝胶属实际安全无毒。
根据2002年版《消毒技术规范》第二部分2.3.3进行一次完整皮肤刺激试验，取上述各实施例1-4口腔护理凝胶对家兔最高皮肤刺激反应积分均值为0，属于无刺激性。
根据2002年版《消毒技术规范》第二部分2.3.5进行阴道黏膜刺激试验，取上述各实施例1-4口腔护理凝胶对家兔阴道黏膜刺激反应积分均为0，属于无刺激性。
在口腔清洁后，本发明配方中亲和性高分子化合物能吸附于口腔黏膜表面，对黏膜有持续保护作用，同时高分子化合物，特别是聚丙烯酰基二甲基牛磺酸铵负载的抗菌活性成分缓慢释放，能够发挥持久抗幽门螺杆菌和杀口腔中其他厌氧菌和好氧菌作用，持续抑制口腔细菌滋生，有效辅助预防各种口腔疾病和胃溃疡、十二指肠溃疡、胃癌等胃病的发生。此外本发明的口腔护理凝胶能有效调整口腔微生物生态平衡、温和无刺激、护齿提神、清新口气，且功能广，可作为牙膏使用、或口腔含漱使用、或口腔溃疡等口腔疾病涂敷，多用途合一。
Claims (6)
1.具有持效抗幽门螺杆菌作用的口腔护理凝胶，其特征在于，它包括如下质量百分比的：
2.根据权利要求1所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，其特征在于：所述的杀菌剂为O-伞花烃-5-醇、西吡氯铵或葡萄糖酸氯己定中的一种。
3.根据权利要求1所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，其特征在于：所述的表面活性剂为十二烷基硫酸钠、椰油酰胺丙基甜菜碱或泊洛沙姆407中的一种。
4.根据权利要求1所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，其特征在于：所述的纳米铂金微量浓度为0.5ppm-5ppm。
5.根据权利要求1所述具有持效抗幽门螺杆菌作用的口腔护理凝胶，其特征在于：所述的纳米铂金的粒径范围在0.5nm-5.0nm。
6.一种如权利要求1所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶的制备方法，其特征在于：包括以下步骤：
(1)将配方中的纯化水分成两份，一份纯化水加入按配比量称取的羧甲基纤维素、聚丙烯酰基二甲基牛磺酸铵中搅拌溶解30—40min，直至变成透明凝胶状，得体系A；
(2)按配比量称量表面活性剂、甘草酸、木糖醇、薄荷醇加入另一份纯化水中，在40—50℃温度下搅拌至完成溶解，得体系B；
(3)将配比量的杀菌剂、纳米铂金、肉豆蔻酸异丙酯加入到体系B中，搅拌均匀，得体系C。
(4)在搅拌的条件下，将体系C加入体系A中，混合均匀，即得所述的具有持效抗幽门螺杆菌作用的口腔护理凝胶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011480380.5A CN112545978A (zh) | 2020-12-15 | 2020-12-15 | 具有持效抗幽门螺杆菌作用的口腔护理凝胶及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011480380.5A CN112545978A (zh) | 2020-12-15 | 2020-12-15 | 具有持效抗幽门螺杆菌作用的口腔护理凝胶及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112545978A true CN112545978A (zh) | 2021-03-26 |
Family
ID=75062937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011480380.5A Pending CN112545978A (zh) | 2020-12-15 | 2020-12-15 | 具有持效抗幽门螺杆菌作用的口腔护理凝胶及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112545978A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730641A (zh) * | 2021-09-28 | 2021-12-03 | 珠海金标生物科技有限公司 | 一种缓释抗菌的敷料及其制备方法 |
| CN113842336A (zh) * | 2021-10-29 | 2021-12-28 | 重庆登康口腔护理用品股份有限公司 | 一种固体漱口水及其制备方法 |
| RU2788728C1 (ru) * | 2022-01-17 | 2023-01-24 | Георгий Александрович Фролов | Композиция с пролонгированным биоцидным эффектом и ополаскиватель полости рта на ее основе |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008120789A (ja) * | 2006-10-18 | 2008-05-29 | Asahi Kasei Chemicals Corp | ピロリ菌の抑制剤または静菌剤 |
| CN101327266A (zh) * | 2008-07-18 | 2008-12-24 | 南方医科大学 | 一种防治由幽门螺杆菌感染引起的口腔疾病的口腔护理剂 |
| JP2014034538A (ja) * | 2012-08-08 | 2014-02-24 | Ibio Epoch:Kk | 練歯磨剤及びその製造方法並びに液体歯磨き |
| CN107281095A (zh) * | 2017-06-26 | 2017-10-24 | 尚蒙科技无锡有限公司 | 一种妇科用抗菌养护凝胶 |
| CN111358721A (zh) * | 2020-04-12 | 2020-07-03 | 广东医创时代科技发展有限公司 | 一种防治口腔幽门螺杆菌感染和多种口腔疾病的中草药口腔护理产品 |
| CN111714625A (zh) * | 2020-07-14 | 2020-09-29 | 湖南大海医药集团有限公司 | 杀灭或抑制口腔内幽门螺旋杆菌的抑菌膏及其制备方法 |
-
2020
- 2020-12-15 CN CN202011480380.5A patent/CN112545978A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008120789A (ja) * | 2006-10-18 | 2008-05-29 | Asahi Kasei Chemicals Corp | ピロリ菌の抑制剤または静菌剤 |
| CN101327266A (zh) * | 2008-07-18 | 2008-12-24 | 南方医科大学 | 一种防治由幽门螺杆菌感染引起的口腔疾病的口腔护理剂 |
| JP2014034538A (ja) * | 2012-08-08 | 2014-02-24 | Ibio Epoch:Kk | 練歯磨剤及びその製造方法並びに液体歯磨き |
| CN107281095A (zh) * | 2017-06-26 | 2017-10-24 | 尚蒙科技无锡有限公司 | 一种妇科用抗菌养护凝胶 |
| CN111358721A (zh) * | 2020-04-12 | 2020-07-03 | 广东医创时代科技发展有限公司 | 一种防治口腔幽门螺杆菌感染和多种口腔疾病的中草药口腔护理产品 |
| CN111714625A (zh) * | 2020-07-14 | 2020-09-29 | 湖南大海医药集团有限公司 | 杀灭或抑制口腔内幽门螺旋杆菌的抑菌膏及其制备方法 |
Non-Patent Citations (5)
| Title |
|---|
| 余传隆: "《中国临床药物大辞典 化学药卷 （下卷）》", 31 August 2018, 中国医药科技出版社 * |
| 国家药典委员会: "《中华人员共和国药典 临床用药须知 化学药和生物制品卷 2010年版》", 30 April 2011, 中国医药科技出版社 * |
| 大连神华: "《大连神华机械》", 26 October 2018 * |
| 裘炳毅 等: "《现代化妆品科学与技术 中》", 31 March 2016, 中国轻工业出版社 * |
| 郑俊民: "《药用高分子材料学 第三版》", 31 January 2009, 中国医药科技出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730641A (zh) * | 2021-09-28 | 2021-12-03 | 珠海金标生物科技有限公司 | 一种缓释抗菌的敷料及其制备方法 |
| CN113842336A (zh) * | 2021-10-29 | 2021-12-28 | 重庆登康口腔护理用品股份有限公司 | 一种固体漱口水及其制备方法 |
| RU2788728C1 (ru) * | 2022-01-17 | 2023-01-24 | Георгий Александрович Фролов | Композиция с пролонгированным биоцидным эффектом и ополаскиватель полости рта на ее основе |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4927634A (en) | Pharmaceutical compositions containing dyclonine HC1 and phenol | |
| EP0565134B1 (en) | Disinfecting compositions and methods therefor | |
| US5560906A (en) | Non-alcoholic antimicrobial mouthwash for removal of dental plaque | |
| RU2558061C2 (ru) | Антисептическая фармацевтическая композиция для гигиены полости рта и лечения заболеваний полости рта микробного происхождения | |
| US20110229534A1 (en) | Non-Irritating Oral Care Formulations | |
| CN112545978A (zh) | 具有持效抗幽门螺杆菌作用的口腔护理凝胶及其制备方法 | |
| CN108042420B (zh) | 一种用于口腔保健的组合物及其应用 | |
| WO2014095489A1 (en) | Topical oral composition for alleviating dry mouth symptoms and for treating mouth ulcers | |
| US4808410A (en) | Pharmaceutical compositions containing dyclonine HC1 and phenol | |
| CN113081900B (zh) | 一种漱口液及其制备方法和应用 | |
| EP1450825A1 (de) | Verwendung von selenithältigen verbindungen zur topischen oder bukkalen anwendung | |
| CN109010098A (zh) | 抗菌漱口液及其制备方法 | |
| US5167952A (en) | Therapeutic composition formulated as a dental rinse that stimulates Prostaglandin synthesis in the mouth to prevent plaque buildup on the teeth and Periodontal disease | |
| DE102015218892A1 (de) | Applikationsgemisch zur Erhöhung der Wirkung von Antiseptika und/oder Desinfektionsmitteln, Applikationsmittel mit dem Gehalt des Applikationsgemischs und die Verwendung dieses Gemischs | |
| CN110974724B (zh) | 一种含透明质酸的组合物及其制备方法和应用 | |
| WO1992018091A1 (en) | Antimicrobial oral compositions | |
| CN109512683B (zh) | 一种聚维酮碘组合物及其制备方法与应用 | |
| CN114796260B (zh) | 一种口腔护理组合物及其制备方法 | |
| KR20170051006A (ko) | 이소프로필메틸페놀과 구강조직수렴제를 함유하는 구강 조성물 | |
| KR20160061852A (ko) | 금속이온 봉쇄제와 이소프로필메틸페놀을 함유하는 구강 조성물 | |
| RU2813879C1 (ru) | Противовоспалительная композиция (варианты) для местного применения в полости рта и верхних дыхательных путях | |
| Shahidulla et al. | HERBAL MOUTHWASH: AN INNOVATIVE APPROACH | |
| RU2691410C1 (ru) | Средство для ухода за полостью рта и горла | |
| KR100665891B1 (ko) | 하이드록시타이로졸을 함유한 구강위생 증진용 조성물 | |
| RU2351313C1 (ru) | Состав для лечения заболеваний полости рта |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210326 |
|
| RJ01 | Rejection of invention patent application after publication |